Vyant Bio Stock (NASDAQ:VYNT)
Previous Close
$NaN
52W Range
$0.26 - $0.26
50D Avg
-
200D Avg
-
Market Cap
-
Avg Vol (3M)
$17.86K
Beta
0.56
Div Yield
-
VYNT Company Profile
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
VYNT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DYAI | Dyadic International, Inc. |
| NTRB | Nutriband Inc. |
| ALGS | Aligos Therapeutics, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| LGVN | Longeveron Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| SRZN | Surrozen, Inc. |
| KA | Kineta, Inc. |
| VRAX | Virax Biolabs Group Limited |
| RNXT | RenovoRx, Inc. |
| RZLT | Rezolute, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| DMAC | DiaMedica Therapeutics Inc. |
| TPST | Tempest Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| FBRX | Forte Biosciences, Inc. |
| KTRA | Kintara Therapeutics, Inc. |